TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1673628

Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.075 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bromocriptine (2.5 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CV 205‐502 and Bromocriptine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CV 205‐502, Bromocriptine, and Normal Controls
Number of subjects: 30
Study: 6813805

Group type: EXPERIMENTAL
Intervention: Gentamicin plus clindamycin for 1 day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefazolin for 1 day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefazolin for 5 days
Number of subjects: 0
Study: 31519130

Group type: EXPERIMENTAL
Intervention: Hyperfractionated, Accelerated Radiotherapy (HART) prescribed as 76 Gy in 56 fractions, 10 fractions weekly; no chemotherapy
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Hyperfractionated, Accelerated Radiotherapy (HART)
Number of subjects: 295
Study: 28656723

Group type: EXPERIMENTAL
Intervention: Stem cell therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional autogenous block grafts
Number of subjects: 18
Study: 26393991

Group type: EXPERIMENTAL
Intervention: EA During HBOT
Number of subjects: 60

Group type: COMPARATOR
Intervention: HBOT
Number of subjects: 60

Group type: COMPARATOR
Intervention: EA
Number of subjects: 60

Group type: COMPARATOR
Intervention: EA Combined With Pure O₂
Number of subjects: 60
Study: 23552462

Group type: EXPERIMENTAL
Intervention: Melanoma skills training using 2 simulation models replicating melanomas and abnormal or benign nevi.
Number of subjects: 74
Study: 21551510

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 19463517

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ezetimibe 5 mg
Number of subjects: 36
Study: 16710429

Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PR)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Scleral buckling (SB)
Number of subjects: 253
Study: 15195061

Group type: EXPERIMENTAL
Intervention: Topical mitomycin C applied to the intact tympanic membrane
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline applied to the intact tympanic membrane (control)
Number of subjects: 15
Study: 11490039

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 22

Group type: COMPARATOR
Intervention: Typical care
Number of subjects: 22
Study: 9766414

Group type: EXPERIMENTAL
Intervention: Transitional care for women with high-risk pregnancies
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pregestational diabetes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Gestational diabetes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reasons for hospitalizations
Number of subjects: 150
Study: 7859799

Group type: EXPERIMENTAL
Intervention: Lifibrol 150 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Lifibrol 300 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Lifibrol 450 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Lifibrol 600 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Lifibrol (high baseline levels > 30 mg.dl-1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 2702158

Group type: EXPERIMENTAL
Intervention: Collagen fleece implanted in osseous defect
Number of subjects: 70

Group type: COMPARATOR
Intervention: Iodoform gauze packed in osseous defect
Number of subjects: 70
Study: 31600432

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD), 12 sessions
Number of subjects: 31
Study: 28403937

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (0.2mg.kg‐1.min‐1 for 14h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 26680421

Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT; n = 20)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low Intensity Training (LIT; n = 23)
Number of subjects: 43
Study: 23414245

Group type: EXPERIMENTAL
Intervention: Test-A (15% NovaMin(®) and NaF)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Test-B (15% NovaMin(®))
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study: 21154218

Group type: EXPERIMENTAL
Intervention: Ketamine (0.23 mg/kg bolus followed by 0.64 mg/kg/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study: 18450360

Group type: EXPERIMENTAL
Intervention: Levovist (galactose-based air-filled microbubbles)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sonovue (sulphur hexafluoride-filled microbubbles)
Number of subjects: 138
Study: 17598307

Group type: EXPERIMENTAL
Intervention: DLF-task group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DLI-task group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 12560955

Group type: COMPARATOR
Intervention: Supramaximal electrical stimulation of common peroneal nerve in bipedal stance
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supramaximal electrical stimulation of common peroneal nerve in monopedal stance
Number of subjects: 20
Study: 10696840

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment for large adenomas and early colorectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening strategies including endoscopy and fecal occult blood tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy as a diagnostic tool
Number of subjects: 0
Study: 9095879

Group type: EXPERIMENTAL
Intervention: Tegaderm dressing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Opsite IV3000 dressing
Number of subjects: 100
Study: 8245326

Group type: EXPERIMENTAL
Intervention: Invasive strategy (1,681 patients)
Number of subjects: 3187

Group type: COMPARATOR
Intervention: Conservative strategy (1,658 patients)
Number of subjects: 3187
Study: 3888709

Group type: EXPERIMENTAL
Intervention: 0.1% domoprednate
Number of subjects: 85

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate
Number of subjects: 85
Study: 29609930

Group type: EXPERIMENTAL
Intervention: Horticulture-related activities (HRAs) including floral arranging, planting, and flower pressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group activities (individual favorite indoor activities)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Horticulture-related activities (HRAs)
Number of subjects: 20
Study: 26771854

Group type: EXPERIMENTAL
Intervention: Surgical treatment for recurrent vestibular schwannoma (Group A: previously operated on and received postoperative radiosurgery; Group B: previously operated on but did not receive postoperative radiosurgery)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Surgical treatment for recurrent vestibular schwannoma (Group A and B)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Surgical treatment for recurrent vestibular schwannoma
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (Group C: primarily operated on VS)
Number of subjects: 53
Study: 23934538

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus acidophilus and Bifidobacteria lactis 2 × 10^E CFU/d
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 49
Study: 23214247

Group type: EXPERIMENTAL
Intervention: CCS combined with NBT and YB capsules
Number of subjects: 65

Group type: COMPARATOR
Intervention: CCS with NBT only
Number of subjects: 65
Study: 20164307

Group type: EXPERIMENTAL
Intervention: Lysine intake of 104.9 mg . kg(‐1) . d(‐1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lysine intake of 117.6 mg . kg(‐1) . d(‐1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Graded intakes of lysine
Number of subjects: 11
Study: 17515572

Group type: EXPERIMENTAL
Intervention: Trastuzumab 4 mg/kg (day 1), followed by 2 mg/kg weekly, plus docetaxel 75 mg/m2 every 3 weeks, and carboplatin (area under curve, 6) for six cycles before surgery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy (docetaxel and carboplatin)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 70
Study: 16135575

Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine 25 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 14588285

Group type: EXPERIMENTAL
Intervention: Provocative discography in subjects with mild persistent low back pain
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (52 subjects with chronic low back pain illness)
Number of subjects: 25
Study: 10458713

Group type: EXPERIMENTAL
Intervention: Aspirin treatment for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 60
Study: 7541660

Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no growth factor)
Number of subjects: 76
Study: 2218849

Group type: COMPARATOR
Intervention: Medical treatment (control of risk factors for stroke including hypertension, diabetes, and hyperlipidemia, and antiplatelet aggregant medication)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Medical treatment plus superficial temporal‐to‐middle cerebral artery bypass
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Medical treatment plus carotid endarterectomy
Number of subjects: 36
Study: 810270

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate inhalation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cold room exposure (3 degrees C)
Number of subjects: 8
Study: 31087723

Group type: EXPERIMENTAL
Intervention: Disulfiram treatment for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 70
Study: 28871440

Group type: EXPERIMENTAL
Intervention: Triheptanoin (C7)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Trioctanoin (C8)
Number of subjects: 32
Study: 26475215

Group type: EXPERIMENTAL
Intervention: Total WBC counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphocyte counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood CRP, interleukin-6, and leptin
Number of subjects: 0
Study: 23982574

Group type: EXPERIMENTAL
Intervention: Robotic virtual reality simulation training plus standard robotic orientation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard robotic orientation alone
Number of subjects: 18
Study: 22047664

Group type: EXPERIMENTAL
Intervention: 100 IU of hCG
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: 200 IU of hCG
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: 500 IU of hCG
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (no hCG)
Number of subjects: 167
Study: 19095174

Group type: EXPERIMENTAL
Intervention: Interventions compared in RCTs with negative results
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16454830

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin, arbekacin inhalation, and oral sulfamethoxazole/trimethoprim (Group C)
Number of subjects: 72

Group type: COMPARATOR
Intervention: MRSA-positive not eradicated (Group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: MRSA-negative (Group A)
Number of subjects: 72
Study: 14569279

Group type: EXPERIMENTAL
Intervention: First Step Program (FSP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 10772515

Group type: EXPERIMENTAL
Intervention: 7F Tail stent
Number of subjects: 60

Group type: COMPARATOR
Intervention: 7F double-pigtail stent
Number of subjects: 60
Study: 9494767

Group type: EXPERIMENTAL
Intervention: TCu220C
Number of subjects: 4673

Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 4673
Study: 8375242

Group type: EXPERIMENTAL
Intervention: Ala 20 g orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ala 40 g orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terbutaline 2.5 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terbutaline 5.0 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline 0.25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 0.4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nondiabetic subjects (placebo)
Number of subjects: 12
Study: 2437789

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 28857147

Group type: EXPERIMENTAL
Intervention: Aminophylline (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambrisentan (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminophylline + Ambrisentan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26892848

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129
Study: 25074072

Group type: EXPERIMENTAL
Intervention: EE/NGM (ethinyl estradiol and norgestimate)
Number of subjects: 201

Group type: COMPARATOR
Intervention: EE/DSG (ethinyl estradiol and desogestrel)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: EE/NGM
Number of subjects: 201

Group type: COMPARATOR
Intervention: EE/DSG
Number of subjects: 201
Study: 22705390

Group type: EXPERIMENTAL
Intervention: Increased schooling (randomized intervention)
Number of subjects: 0
Study: 20420792

Group type: COMPARATOR
Intervention: Dorixina Forte (reference product)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prestodol (test formulation)
Number of subjects: 26
Study: 17651517

Group type: EXPERIMENTAL
Intervention: 15 mg Zn/d
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 15961582

Group type: EXPERIMENTAL
Intervention: In utero exposure to background levels of PCBs (low exposure category <1.25 microg of PCB/liter of serum)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: In utero exposure to background levels of PCBs (high exposure category >=5 microg of PCB/liter of serum)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Increase in PCB level (microg/liter)
Number of subjects: 894
Study: 12756570

Group type: EXPERIMENTAL
Intervention: Eccentric training at 180 degrees s(‐1) (3.14 rad s(‐1))
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Eccentric training at 30 degrees s(‐1) (0.52 rad s(‐1))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 26
Study: 10332784

Group type: EXPERIMENTAL
Intervention: Functional evaluation by machine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 0
Study: 8945796

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 1769635

Group type: COMPARATOR
Intervention: Clonidine (2 x 75 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nifedipine (2 x 20 mg retard)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of Clonidine and Nifedipine (C/N)
Number of subjects: 10
Study: 7038497

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31479003

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost for 5 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28794410

Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene care programme (AOHCP) comprising a powered toothbrush, 0.2% chlorhexidine mouthrinse, and oral hygiene instruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene care programme (AOHCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional oral hygiene care programme (COHCP)
Number of subjects: 0
Study: 26470711

Group type: EXPERIMENTAL
Intervention: Zirconia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lithium disilicate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Titanium
Number of subjects: 24
Study: 23126237

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (160/4.5 μg 1 inhalation twice daily plus as-needed budesonide/formoterol 160/4.5 μg)
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Budesonide/formoterol plus terbutaline (160/4.5 μg 1 inhalation twice daily plus as-needed terbutaline 0.4 mg)
Number of subjects: 2091
Study: 21816079

Group type: EXPERIMENTAL
Intervention: Computerised cognitive rehabilitation training (16 sessions lasting 8 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 61
Study: 20101851

Group type: EXPERIMENTAL
Intervention: Follitropin alpha exclusively
Number of subjects: 70

Group type: COMPARATOR
Intervention: Follitropin alpha with 25 IU human chorionic gonadotropin (hCG) daily
Number of subjects: 70
Study: 16965680

Group type: EXPERIMENTAL
Intervention: NP (NVB plus DDP)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: TP (TAX plus DDP)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: GP (GEM plus DDP)
Number of subjects: 276
Study: 15605667

Group type: EXPERIMENTAL
Intervention: lumiracoxib 200mg o.d.
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400mg o.d.
Number of subjects: 1124

Group type: COMPARATOR
Intervention: naproxen 500mg twice daily
Number of subjects: 1124

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1124
Study: 11689729

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) for 8 weeks, 3 times per week.
Number of subjects: 25
Study: 8993241

Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Aprotinin and Placebo
Number of subjects: 106
Study: 8333639

Group type: EXPERIMENTAL
Intervention: 0.6 mg IM atropine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 55
Study: 3552537

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 49
Study: 31944310

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28869825

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus the Memory Support Intervention (CT + Memory Support)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cognitive therapy-as-usual (CT-as-usual)
Number of subjects: 48
Study: 27468795

Group type: EXPERIMENTAL
Intervention: Propolis + SRP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo + SRP
Number of subjects: 50
Study: 25559332

Group type: EXPERIMENTAL
Intervention: Qur'an recitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 23626461

Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg plus Metformin
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 20655750

Group type: EXPERIMENTAL
Intervention: Faster gait
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Shorter steps
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: One-standard-deviation decrease in gait speed
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: One-standard-deviation decrease in step length
Number of subjects: 57
Study: 18266400

Group type: EXPERIMENTAL
Intervention: Alendronic acid 5 mg/day
Number of subjects: 138

Group type: COMPARATOR
Intervention: Risedronic acid 2.5 mg/day
Number of subjects: 138
Study: 15932834

Group type: EXPERIMENTAL
Intervention: Extended regimen of norelgestromin/ethinyl E2 transdermal patch (weekly application for 12 consecutive weeks, 1 patch-free week, and 3 more consecutive weekly applications, n = 158)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Cyclic regimen (4 consecutive cycles of 3 weekly applications and 1 patch-free week, n = 81)
Number of subjects: 239
Study: 12792297

Group type: EXPERIMENTAL
Intervention: E(2)/NETA (0.025/0.125 mg/day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 124
Study: 11126377

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAI with systemic chemotherapy following hepatic resection
Number of subjects: 0
Study: 8971665

Group type: EXPERIMENTAL
Intervention: Needles that remained in place for 10 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxa-only treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holistic acupuncturist (regardless of gender)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holistic treatment style
Number of subjects: 0
Study: 1459154

Group type: EXPERIMENTAL
Intervention: 1 mg KLH per month for up to 1 year
Number of subjects: 17

Group type: COMPARATOR
Intervention: No immunostimulator (control group)
Number of subjects: 17
Study: 6695853

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IF RT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Involved field radiotherapy (IF RT) plus six cycles of combination chemotherapy (CT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Total nodal radiation (TNR)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Total nodal radiation (TNR) plus CT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 68
Study: 31162177

Group type: EXPERIMENTAL
Intervention: Monocular vision in glaucoma patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Binocular vision in glaucoma patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 84

Group type: COMPARATOR
Intervention: Young controls
Number of subjects: 84